This is a review of the pharmacology, pharmacokinetics, side-effects, antiepileptic efficacy and clinical usage of oxcarbazepine, an antiepileptic drug newly licensed in the UK and USA.
INTRODUCTION
Oxcarbazepine recently gained a licence in the UK and USA. The purpose of this article is to review the pharmacology and therapeutics of oxcarbazepine for those prescribers unfamiliar with this interesting new antiepileptic drug [1] [2] [3] . Although only newly licensed in the UK and USA, oxcarbazepine has in fact been in routine clinical use in Denmark and other countries for up to 10 years, and experience of more than 200 000 patients years has been gained. Within the regulatory database, there are detailed records of around 7000 patients worldwide. This is an unusually large experience, and oxcarbazepine comes into practice within the UK with a great deal of background data concerning its pharmacological and clinical properties, and a wide range of indications. Indeed, oxcarbazepine is already considered a first line therapy in certain countries for a range of epilepsy indications 1 .
PHYSICAL AND CHEMICAL CHARACTERISTICS
Oxcarbazepine is the 10 keto analogue of carbamazepine. It is a neutral lipophilic compound, and, like carbamazepine, very insoluble in water. It is not clear whether it is as unstable in humid conditions as is carbamazepine. The antiepileptic action of carbamazepine is, like carbamazepine [3] [4] [5] [6] [7] , thought to be due primarily to blockage of voltage sensitive sodium channels resulting in stabilization of hyper-excited neural membranes, inhibition of repetitive neuronal firing and inhibition of the spread of discharges. It also increases potassium conductance, reduces glutaminergic transmission and modulates calcium channel function. The rationale behind its original development was to use the parent molecule carbamazepine as a template, and to produce a drug as effective as carbamazepine, but with an improved side-effect profile. A key difference between the two drugs is that oxcarbazepine unlike carbamazepine is not metabolized to an epoxide derivative. As the epoxide is responsible for some of the toxic effects of carbamazepine, the lack of epoxidation of oxcarbazepine is probably one reason for its better sideeffect profile. Its biotransformation is largely by hydroxylation, to an active non-toxic 10-monohydroxy metabolite (MHD: 10,11 dihydro-10-hydroxy-5H-dibenzol[b,f]azepine-5-carboxamide) 8 . The pharmacological action of the drug is exerted primarily though this metabolite, and oxcarbazepine is in essence a prodrug of MHD.
PHARMACOKINETICS Absorption and distribution
Oxcarbazepine is absorbed almost completely after oral ingestion, and this is an advantage over carbamazepine. Absorption is not affected by food 9 . Ox-carbazepine is rapidly and almost completely metabolized to the biologically active 10-monohydroxy metabolite MHD. Following ingestion, there is little parent drug circulating in the plasma, although MHD is widely distributed to brain and other lipid tissues 1-3, 8, 10, 11 . The volume of distribution is 0.3-0.8 l/kg and it is 38% bound to plasma proteins. Foetal and maternal plasma concentrations of the drug are similar (as judged by the neonatal and maternal levels in one case) and the plasma: breast milk ratio of oxcarbazepine is 0.5.
Biotransformation and excretion
Oxcarbazepine is rapidly and extensively metabolized in the liver via a reductive pathway, and less than 1% of the drug is excreted unchanged in the urine 1-3, 8, 10, 11 (Fig. 1) . The primary metabolite MHD is conjugated to a glucuronide compound. It is not subject to epoxidation as is the case of carbamazepine. The biotransformation is rapid and almost complete, and only trace amounts of oxcarbazepine are found in the blood. A small amount of a dihydroxy derivative (DHD) is also formed. Peak serum concentrations of MHD are reached in 4-6 hours. The plasma half life of MHD is about 8-10 hours, and is not altered by concomitant antiepileptic drug therapy. There is a linear relationship between dose and serum levels of the drug and its metabolite in the usual clinical dose ranges. The drug is largely excreted by the kidneys, 83% as MHD or its glucuronide, 4-7% as the DHD, and 0.3-3% as oxcarbazepine. Due to this dependency on renal excretion, the dose of oxcarbazepine may need to be reduced in the presence of severe renal impairment 12 .
Drug interactions
Oxcarbazepine results in only a very low level of hepatic cytochrome P450 enzyme induction, and this is a great advantage over carbamazepine. There is no auto-induction, and there are fewer interactions of oxcarbazepine with other drugs than observed with carbamazepine 1-3, 10, 11 . Most cytochrome P450 enzymes are unaffected by the drug (including CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9, CYP4A11), and thus the common interactions typical of carbamazepine, for instance, are absent. Oxcarbazepine therefore does not usually alter the levels of the other commonly used antiepileptic drugs. Conversely, the enzyme-inducing effect of carbamazepine, phenytoin and phenobarbital can reduce the bioavailability of MHD, and the oxcarbazepine dose may need to be higher in some patients who are co-medicated with these drugs 13 . As oxcarbazepine results in less liver enzyme induction than carbamazepine, it has fewer effects on thyroid or sex hormones 14, 15 . Oxcarbazepine has been shown not to induce the metabolism or interact with other non-epileptic drugs such as warfarin, cimetidine, erythromycin, verapamil or dextropropoxyphene 1-3, 10, 11 . The only cytochrome P450 enzymes inhibited by oxcarbazepine are CYP2C19, CYP3A4 and CYP3A5. As a result, oral contraceptive levels may be lower on co-medication with oxcarbazepine. Due to this potential interaction, women medicated with oxcarbazepine who require the contraceptive pill should take a high (50 µg) oestrogen formulation, and be warned about the potential hazard to contraception 16, 17 . There is insufficient data to make any statement about its safety in pregnancy, and the drug should be not be used in pregnant patients.
SIDE-EFFECTS
The side-effect profile of oxcarbazepine is similar in nature to that of carbamazepine, although the frequency and severity of side-effects have been shown to be less 1, 3, 11, 18, 19 . The commonest dose-related sideeffects are fatigue, headache, dizziness and ataxia. In a comparative monotherapy trial in 235 outpatients with newly diagnosed epilepsy, some sideeffects were reported by 68% receiving oxcarbazepine and 74% receiving carbamazepine, but the mean number of side-effects per patient was lower with oxcarbazepine compared with carbamazepine (2.8 vs. 3.5) 18 . Other side-effects included nausea and gastrointestinal disturbance. Two studies have shown no impairment of cognitive function after 4-12 months of therapy with oxcarbazepine 20, 21 . In the comparative randomized controlled trials in both adults and children, the side-effect profile of the drug was better than with carbamazepine or phenytoin, and oxcarbazepine scored better on patients' and physicians' rating scales than carbamazepine, valproate or phenytoin [1] [2] [3] 11 . The withdrawal rates from sideeffects in the published monotherapy studies of oxcarbazepine can be take as a good index of tolerability. These were better on oxcarbazepine when compared to published studies of carbamazepine, valproate and phenytoin (Table 1 ). There has been no published comparison of the tolerability of oxcarbazepine and newer antiepileptic drugs or slowrelease carbamazepine, which would be of interest in view of the improved tolerability of the slow release compared to the standard carbamazepine formulation.
Skin rash is relatively common 19 (up to 10% of all patients) and is the main reason for discontinuation of the drug in the comparative monotherapy studies 1-3, 11, 19 . The rash is similar to that of a Includes one patient on methotrexate with toxic megacolon and reversible bone marrow suppression, one patient with raised intracranial pressure (an astrocytoma was diagnosed after enrollment), two pregnancies, one suicide attempt, and one report each of abdominal pain, psychosis, tongue ulceration, and psychic lability. b Includes one report each of abnormal vision, headache, leucopenia, and raised liver parameters. c Includes one report each of embolism and abdominal pain.
carbamazepine, although cross-reactivity with carbamazepine is present in only about 25-30% of cases, and so oxcarbazepine is a useful drug in patients who are shown to have carbamazepine hypersensitivity 1, 11 . Oxcarbazepine, like carbamazepine, may cause hyponatraemia presumably due to an antidiuretic hormone-like effect 24, 25 . The effect seems to be greater with oxcarbazepine than carbamazepine, and about 20% of all patients show a serum sodium level below 135 mmol/l. The degree of hyponatraemia is however usually mild and is generally asymptomatic and not of clinical importance. It is a dose-dependant effect, and alleviated by dose reduction or water restriction. The incidence of marked hyponatraemia (below 125 mmol/l) was only 2.7%, in our study, and was generally asymptomatic 26 . There is no need to monitor the sodium levels regularly, unless there are special risks (e.g. in patients taking diuretics or in the elderly).
ANTIEPILEPTIC EFFECT
Oxcarbazepine was first subjected to clinical trials in the 1980s 1-3, 11, 19 and it was on this basis that the drug was licensed in Denmark and other countries. A large number of open clinical trial were published, and considerable experience with the drug obtained. A further clinical trial programme was embarked upon in the early 1990s, in order to comply with GCP (Good Clinical Practice) guidelines and to allow the drug to be put forward for licens-ing in the USA, UK and more widely in Europe. This trial programme has now been successfully completed, and the antiepileptic efficacy of the drug has been proven beyond question 2, 3, 11, 18, 23, 24, 26, 27 . Significant superiority of oxcarbazepine over placebo was demonstrated in the add-on trials in adults and children. In adults, the median reduction in partial seizure frequency was between 26% (600 mg/day) and 40% (2400 mg/day), and the number of responders (>50% reduction in seizure frequency) was also significantly greater on 2400 mg than 600 mg/day (50% vs. 27%, respectively). (Barcs et al, submitted to Epilepsia). Furthermore, oxcarbazepine has been tested in four randomized double-blind monotherapy trials, including one short-term study of patients being evaluated for epilepsy surgery 29 , one study in new patients 30 and two monotherapy substitution studies in refractory cases 31, 32 . All four studies demonstrated that a high dose of the drug was either superior to placebo or to a low dose [29] [30] [31] [32] . An excellent feature of the trial programme is that comparative data was also obtained comparing oxcarbazepine to other established antiepileptic drugs (and not just placebo) 18, 19, 22 . These trials have shown that oxcarbazepine is at least as effective as carbamazepine, valproate and phenytoin and superior to placebo, and had superior tolerability when compared to the other antiepileptics. Significantly fewer patients treated with oxcarbazepine necessitated withdrawal due to sideeffects oxcarbazepine as add-on therapy show a linear dose response relationship.
One key advantage of oxcarbazepine is less enzyme induction than many other antiepileptic drugs, including carbamazepine, leading to fewer drug interactions. If oxcarbazepine is being substituted for carbamazepine, care is needed, as de-induction could alter levels of concomitant medication. The only clinically significant interaction for oxcarbazepine is with the contraceptive pill, and high dose oestrogen contraceptives (50 µg) should be used, patients warned about the risks of drug interaction and the potential for contraceptive failure discussed. One particular indication for oxcarbazepine is as an alternative to carbamazepine in patients who develop a carbamazepineinduced rash. Studies have shown that there is only about 25-30% cross-sensitivity 19 .
The most common chronic effect with oxcarbazepine is hyponatraemia, but this is usually mild, asymptomatic and of no clinical significance. The hyponatraemia is likely to be possibly due to a marked antidiuretic effect, and the consumption of large fluid volumes (including large quantities of beer) should be discouraged. This is of particular relevance to younger patients. In routine clinical practice, serum sodium need not be monitored, unless there are special risks (e.g. in patients taking diuretics or in the elderly).
Anecdotal clinical practice in Denmark suggests that oxcarbazepine can be substituted for carbamazepine rapidly-within one dose-replacing carbamazepine with oxcarbazepine in a dosing ratio of 200 mg : 300 mg with no need for titration. It than phenytoin or carbamazepine 18, 19 . A therapeutic range of MHD of 50-125 µmols/l has been suggested. Similarly, in children, oxcarbazepine was at least as effective as phenytoin but had improved tolerability 23 .
A large retrospective post-marketing study, analysing 10 years clinical experience with the drug has been reported in 947 patients. Eighty-two percent of patients were switched from other AEDs to oxcarbazepine (68% from carbamazepine) 33 . Sixty-three percent of patients were receiving monotherapy. Oxcarbazepine significantly reduced seizure frequency in 32-48% of patients. In another study of switching patients from carbamazepine to oxcarbazepine, 8% of patients became seizure free and 32% experienced a greater than 50% reduction in seizures. Seventy-nine percent of patients had improved tolerability on oxcarbazepine compared to carbamazepine 34 .
CLINICAL USE IN EPILEPSY
Oxcarbazepine is licensed for use as monotherapy or adjunctive therapy in patients with partial onset seizures with or without secondary generalization. In either situation, its efficacy is excellent, and is at least equivalent to that of other first line drugs. It has a significant effect both in partial and in secondarily generalized seizures in children and in adults. It is also somewhat better tolerated than other first line drugs, and only a small proportion of patients withdraw from therapy in the large comparative clinical trials. Oxcarbazepine is likely to be effective in all situations in which carbamazepine might be used, although its wider use in generalized epilepsy syndromes is relatively unexplored. Recent randomized controlled studies of has been shown that oxcarbazepine can be added to carbamazepine with additive efficacy and acceptable tolerability; further work is needed to confirm this interesting observation.
Oxcarbazepine is currently only available as an oral formulation. It can be introduced more quickly than carbamazepine, and indeed, the starting dose of 600 mg/day is clinically effective. For all patients therapeutic levels of oxcarbazepine can be reached within days of starting treatment. In adults a starting dose of 600 mg/day can be increased weekly in 600 mg increments to a usual maintenance dose of between 900-1200 mg/day in twice daily dosing intervals. The initial dose in children is 10 mg/kg/day increasing in 10 mg/kg steps to 30 mg/kg/day. Because the metabolism of oxcarbazepine is increased by enzyme-inducing drugs, patients co-medicated with phenytoin or phenobarbitone may need somewhat higher doses of oxcarbazepine than for monotherapy; to what extent this is clinically important has not been established, and dosage should be guided by clinical response. In moderate or severe renal failure, the dose of oxcarbazepine may need to be lowered.
